Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cartesian Therapeutics (RNAC) EPS (Weighted Average and Diluted) (2019 - 2025)

Cartesian Therapeutics (RNAC) has disclosed EPS (Weighted Average and Diluted) for 7 consecutive years, with -$3.46 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 152.42% to -$3.46 in Q4 2025 year-over-year; TTM through Dec 2025 was -$5.02, a 11.8% decrease, with the full-year FY2025 number at -$5.02, down 11.8% from a year prior.
  • EPS (Weighted Average and Diluted) was -$3.46 for Q4 2025 at Cartesian Therapeutics, down from -$1.38 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $6.6 in Q4 2024 to a low of -$41.56 in Q4 2023.
  • A 5-year average of -$2.86 and a median of -$0.12 in 2021 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): skyrocketed 3043.6% in 2022, then crashed 415700.0% in 2023.
  • Cartesian Therapeutics' EPS (Weighted Average and Diluted) stood at $0.12 in 2021, then plummeted by 91.67% to $0.01 in 2022, then tumbled by 415700.0% to -$41.56 in 2023, then skyrocketed by 115.88% to $6.6 in 2024, then plummeted by 152.42% to -$3.46 in 2025.
  • Per Business Quant, the three most recent readings for RNAC's EPS (Weighted Average and Diluted) are -$3.46 (Q4 2025), -$1.38 (Q3 2025), and $0.5 (Q2 2025).